ESMO25: On next-generation bispecifics, with Tadaaki Taniguchi

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas, about the new clinical data they presented, including from KEYNOTE-905.

Taniguchi explained what the new data means for muscle-invasive bladder cancer patients who are not eligible for or declined cisplatin-based chemotherapy, and also discussed the first clinical data from Astellas’ investigational CLDN18.2-targeted, next-generation bispecific CD3 T-cell engager ASP2138, as well as the Congress as a whole.

Watch this and other conversations from ESMO 2025 here.